The cow's hearts couldn't cost much to acquire, just get them from the local butcher's.
The chemicals used in ADAPT also couldn't contribute too much to the process - and presumably will go down as a % of cost, the more we produce.
So if the main cost is the labour, which will reduce as skills increase, and presumably the provision of a sterile environment, then I can't imagine it costs $1,000 per patch. Costs will have to come down, and I can't imagine the price will remain at its modest levels, once the treatment becomes the gold standard (notice how SRX are starting to push prices up - even in the USA, where the prices are already higher?).
In a nutshell, what we have right now is likely to be the poor economies of a fledgling operation, coupled with penetration pricing.
Of more concern is how much money they've pissed away on marketing costs. It does indeed look like a CR is on the cards, which is pathetic, really. I had a buy order in at mid 9's. I'll be pulling it and seeing what happens. Dilution or not (which won't be a large % in any case), less than 10c is cheap for what this company will be.
- Forums
- ASX - By Stock
- AVR
- Ann: Half Year Report
Ann: Half Year Report, page-14
-
- There are more pages in this discussion • 133 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$17.91 |
Change
-0.090(0.50%) |
Mkt cap ! $344.2M |
Open | High | Low | Value | Volume |
$18.00 | $18.10 | $17.75 | $74.32K | 4.151K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 681 | $17.90 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$18.25 | 100 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 681 | 17.900 |
1 | 1 | 17.800 |
1 | 443 | 17.700 |
1 | 26 | 17.650 |
1 | 200 | 17.560 |
Price($) | Vol. | No. |
---|---|---|
18.250 | 100 | 1 |
18.300 | 150 | 1 |
18.500 | 43 | 1 |
18.690 | 550 | 1 |
18.750 | 143 | 1 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online